RxSight, Inc. is a company engaged in the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery. The company also provides capital equipment that works in conjunction with these lenses. RxSight's products are primarily used in the medical field to enhance the efficiency and effectiveness of cataract treatments.
- Light Adjustable Lenses (LALs) - Used in cataract surgeries, these lenses are held at customer sites on consignment and revenue is recognized upon implantation in a patient.
- Light Delivery Devices (LDDs) - Deliver light to the LALs to adjust the lens post-surgery, with revenue recognized upon installation and customer acceptance.
- Service Warranty, Service Contracts, and Accessories - Provides ongoing support and additional products, with revenue recognized over the service period.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Ron Kurtz ExecutiveBoard | President and Chief Executive Officer | Ron Kurtz, M.D. has served as the President and Chief Executive Officer of RxSight since 2016 and as a Board Member from that year, demonstrating his leadership experience in the medical device field. | View Report → | |
Eric Weinberg Executive | Co-President and Chief Commercial Officer | Eric Weinberg has served as Co-President and Chief Commercial Officer at RxSight, Inc. since his promotion on July 15, 2024. Prior to that, he joined as Chief Commercial Officer in June 2015 and has held various executive roles at companies including LenSx Lasers, Alcon LenSx, and IntraLase Corp. | ||
Ilya Goldshleger Executive | Co-President and Chief Operating Officer | Ilya Goldshleger is the Co-President and Chief Operating Officer at RxSight, Inc. since July 15, 2024 and has served as Chief Operating Officer since June 2019, after joining as Vice President of Engineering in September 2015 to drive the development of innovative ophthalmic technology. | ||
Shelley Thunen Executive | Co-President and Chief Financial Officer | Board member and audit committee chair at Surface Ophthalmics, Inc. since August 2020; Board member and audit committee chair at Aeon Biopharma, Inc. since June 2023; Board member, audit committee chair, and compensation committee member at LENZ Therapeutics, Inc. since November 2023 | Shelley Thunen serves as Co-President and Chief Financial Officer at RxSight, having joined the company in January 2016 (became CFO in February 2017) and previously held executive roles at Endologix, Alcon LenSx, and IntraLase. | |
J. Andy Corley Board | Chairman of the Board of Directors | Chairman of the Board at Neurolenses, Inc.; Partner at Flying L Partners | J. Andy Corley is the Chairman of the Board of Directors at RXST, serving since July 2015. He brings extensive experience in the medical device industry through leadership roles and board positions at multiple companies. | |
Julie B. Andrews Board | Board Member and Chairperson of the Audit Committee | CFO of Orthofix Medical ; Chair of the Audit Committee at Priveterra | Julie B. Andrews has served as a board member at RXST, where she was nominated as Chairperson of the Audit Committee since August 2021. She is an experienced finance leader with roles as CFO at Orthofix Medical and board leadership at Priveterra. | |
Juliet Tammenoms Bakker Board | Board Member | Board Member of Ceribell, Inc. (NASDAQ:CBLL) | Juliet Tammenoms Bakker has been a board member of RXST since June 2015. With a deep background in healthcare venture capital and corporate governance, she co-founded Longitude Capital in 2006 and has served on multiple boards, contributing to the growth of innovative medical technology companies. | |
Robert J. Palmisano Board | Board Member and Chairperson of the Compensation Committee | Chairman of the Board at Priveterra Acquisition Corp (since December 2020) | Robert J. Palmisano has served as RXST board member and Chairperson of the Compensation Committee since August 2021, bringing extensive leadership experience from previous CEO roles at Wright Medical, ev3 Inc., and IntraLase Corp. | |
Robert Warner Board | Board Member | Board Member at i Lumen Scientific; Chairman at EyeYon Medical; Board Member at GRACE | Robert Warner has served as a Board Member at RXST since August 2021, where he was also nominated to the Compensation Committee and appointed as Chair of the Governance Committee. Previously, he held senior executive roles at Alcon Laboratories from 2005 to 2018. | |
Shweta Singh Maniar Board | Board Member | Global Leader, Healthcare & Life Sciences Solutions & Strategy at Google; Board Member at Orthofix Medical Inc. | Shweta Singh Maniar has been a board member at RXST since December 2021, currently serving on the Corporate Governance and Nominating Committee. She brings extensive leadership experience from roles at Google and as a board member at Orthofix Medical Inc., among other positions. | |
Tamara R. Fountain Board | Board Member (Class III Director) | Faculty at Rush University Medical Center; Private Practice at Ophthalmology Partners, Ltd.; Board Member at Sight Sciences | Dr. Tamara R. Fountain has served as a board member and Audit Committee member at RXST since January 2022, bringing extensive expertise in ophthalmology and leadership from her academic and clinical roles. | |
William J. Link Board | Board Member | Founder and Managing Partner at Flying L Management, LLC; Managing Director and Co-Founder at Versant Ventures Management LLC; Board Member at Horizon Surgical; Board Member at Praxis Management, LLC; Board Member at Lensar, Inc.; Board Member at Tarsus Pharmaceuticals, Inc.; Board Member at Allegro Ophthalmics, LLC; Board Member at Forsight Vision 6; Board Member at TearClear Corp.; Board Member at ViaLase, Inc.; Board Member at Osanni Bio, Inc.; Board Member at EyeDura, Inc. | William J. Link, Ph.D. has served as a Board Member of RXST since November 2016, also serving on the Compensation Committee (2016-2021) and Audit Committee (2021-2024). He has an extensive background in founding and leading healthcare and venture capital firms. |
- Given the lack of a typical March uptick and your cautious view of Q2 volumes, how will you mitigate risks if the LAL volume fails to pick up in the second half as expected?
- With growing competitive pressures and pivotal macroeconomic uncertainties, can you provide more detailed plans on accelerating LAL adoption and countering the impact of competitive trialing by fixed premium lens players?
- As you reduced production in 2025 to align with revised revenue guidance despite last year’s production ramp-up, what specific cost-control initiatives are in place if inventory sales underperform in the latter half of the year?
- In light of recurring workload challenges highlighted by practices, what concrete measures are you implementing to streamline postoperative adjustments, and how will these address capacity constraints to boost overall LAL procedures?
- Given that international expansion is a market-by-market decision and upcoming regulatory approvals are underway, how do you plan to quantify and leverage premium IOL volume gains in regions like South Korea and the U.K. while managing potential tariff risks?
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
According to Market Scope, the global cataract IOL market is highly concentrated, with the top two players accounting for approximately 75% of the total U.S. premium cataract surgery market and approximately 60% of the global manufacturer market revenue. Our competitors are significantly larger than us with greater financial, marketing, sales and personnel resources, greater brand recognition and longer operating histories. The most popular premium IOLs families approved for cataract treatment are toric and multifocal Acrysof and Tecnis IOL models. According to the Market Scope 2024 Premium Report, Alcon is one of the top IOL manufacturers, with an estimated 2024 revenue share of the world-wide premium IOL market of approximately 44%. | |
According to Market Scope, the global cataract IOL market is highly concentrated, with the top two players accounting for approximately 75% of the total U.S. premium cataract surgery market and approximately 60% of the global manufacturer market revenue. Our competitors are significantly larger than us with greater financial, marketing, sales and personnel resources, greater brand recognition and longer operating histories. The most popular premium IOLs families approved for cataract treatment are toric and multifocal Acrysof and Tecnis IOL models. According to the Market Scope 2024 Premium Report, Johnson & Johnson is one of the top IOL manufacturers, with an estimated 2024 revenue share of the world-wide premium IOL market of approximately 24%. |
Recent press releases and 8-K filings for RXST.
- The DJS Law Group is investigating RxSight, Inc. for securities fraud violations on behalf of investors.
- The investigation focuses on whether RxSight issued misleading statements or failed to disclose pertinent information.
- This investigation follows RxSight's Q2 2025 financial results, which reported declines in key metrics, including Light Delivery Devices (LDD) sales and total revenue.
- RxSight also lowered its full-year financial guidance, attributing the change partly to "adoption challenges" and an "LDD stall".
- On the day of the Q2 2025 financial results announcement, shares of RxSight fell by just under 38%.
- The Schall Law Firm is investigating RxSight, Inc. (NASDAQ: RXST) for potential violations of securities laws, focusing on whether the company issued false or misleading statements and/or failed to disclose pertinent information to investors.
- The investigation follows RxSight's Q2 2025 financial results, reported on July 9, 2025, which showed declines in Light Delivery Devices (LDD) sales and light adjustable intraocular lenses (LAL) utilization, alongside an overall revenue decline.
- RxSight lowered its guidance for full year 2025, attributing the LDD stall to "Adoption challenges over the last few quarters".
- Following this news, shares of RxSight fell by 37.8% on July 9, 2025.
- RxSight announced preliminary Q2 2025 revenue of approximately $33.6 million, marking a 4% decrease compared to the prior year period and an 11% decrease compared to the first quarter of 2025.
- This revenue performance was influenced by a 45% decrease in Light Delivery Device (LDD) sales to 40 units compared to Q1 2025, despite a 13% increase in Light Adjustable Lens (LAL®/LAL+®) procedure volume compared to Q2 2024.
- The company revised its full-year 2025 revenue guidance downward to a range of $120.0 million to $130.0 million, from the previous range of $160.0 million to $175.0 million.
- As of June 30, 2025, preliminary cash, cash equivalents, and short-term investments were $227.5 million, a decrease of approximately $1.8 million from March 31, 2025.